Katharine Birkness

Katharine Birkness

Auto-generated profile, based on publicly available information

Katharine Birkness

Queen's University, Faculty of Medicine, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
CSClara Strowel
Clara Strowel
Camille Raynes-GreenowCamille Raynes-Greenow
Camille Raynes-Greenow
LPLily Pham
Lily Pham
SCStephen Carter
Stephen Carter
KBKatharine Birkness
Katharine Birkness
SESarira El-Den
Sarira El-Den
Background: Perinatal depression (PND) screening is often recommended in primary care settings, which includes the community pharmacy setting. However, there is limited research exploring pharmacists’ perspectives on their roles in screening for perinatal mental illness. Aim: This study aimed to explore pharmacists’ views of pharmacists’ roles in PND screening, as well as training and resource needs for PND screening in community pharmacy settings. Method: A questionnaire including three open-ended questions focusing on pharmacists’ perspectives of their role in PND screening, their training, and resource needs in this area, was disseminated to pharmacists across Australia via professional organisations and social media. Each open-ended question was separately analysed by inductive content analysis. Subcategories were deductively mapped to the Theoretical Framework of Acceptability. Results: Responses (N = 149) from the first open-ended question about pharmacists’ roles in PND screening resulted in three categories (PND screening in primary care settings will support the community, community pharmacy environment, and system and policy changes) and ten subcategories. Responses to question two on training needs (n = 148) were categorised as: training content, training length, and training delivery while responses about resource needs (n = 147) fell into three categories: adapting community pharmacy operating structures, pharmacist-specific resources, and consumer-specific resources. Conclusion: While some pharmacists were accepting of a role in PND screening due to pharmacists’ accessibility and positive relationships with consumers, others had concerns regarding whether PND screening was within pharmacists’ scope of practice. Further training and resources are needed to facilitate pharmacists’ roles in PND screening, referral and care.

1 July 2024 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Open access
SESarira El-Den
Sarira El-Den
KBKatharine Birkness
Katharine Birkness
LPLily Pham
Lily Pham
AMAndrea Lynn Murphy
Andrea Lynn Murphy
RMRebekah Moles
Rebekah Moles
SCStephen Carter
Stephen Carter
While pharmacists' roles in mental healthcare are expanding, research exploring pharmacists' acceptability and willingness to provide mental health services is limited. This study developed and validated theory-driven measures of pharmacists' acceptability and willingness to screen for perinatal depression in community pharmacy settings. Items were developed using published literature and the Theoretical Framework of Acceptability (TFA), then content validated using consensus methods with experts who completed the content validity index (CVI). The revised items were disseminated to pharmacists in Australia. Responses were analysed descriptively. Exploratory factor analyses (EFA) were used to explore the factorial structure and generate scales. Multivariate regression analysis was conducted to explore predictors of willingness. A 58-item questionnaire was developed, encompassing the 7 domains of the TFA and an eighth domain (willingness). The average CVI was 0.92, domain range (0.88-0.96). The universal CVI was 56/58. Expert feedback informed item revision, creation and deletion. Pharmacists' responses (n = 157) to the final 42-item questionnaire indicated overall acceptance and willingness to conduct PND screening. However, perceived knowledge was lacking. The EFA resulted a two-factor solution (1 = acceptance; 2 = self-efficacy). The measurement scales created had good internal consistency. In multivariate regression analysis, 'Acceptance' (Beta = 0.949 (0.760-1.103)) and 'Self-Efficacy' (Beta = 0.107 (0.036-0.174)) were significant predictors of 'Willingness' and the model predicted 77 % of the variation in 'Willingness'. Psychometrically-sound measures of pharmacists' acceptability and willingness to screen for PND have been developed with stakeholder input. The questionnaire can be used for standardised measurement of these constructs across studies.

4 December 2023 in Canadian Journal of Bioethics / Revue Canadienne de Bioéthique
Verified
Journal Article
Open access
KBKatharine Birkness
Katharine Birkness
ARAbraham Rudnick
Abraham Rudnick
L’aide médicale à mourir (AMM) devrait être légalisée au Canada à partir de mars 2024 pour les personnes dont la seule condition médicale sous-jacente est un trouble ou une maladie mentale (AMM MM-SCMS). Dans le cadre de l’élaboration de lignes directrices visant à assurer la sécurité et la cohérence de l’AMM MM-SCMS, il convient d’accorder une attention suffisante à l’interprétation de la terminologie ambiguë de la législation actuelle et de veiller à ce que ces interprétations soient fondées sur des principes éthiques acceptables.